Form 8-K - Current report:
SEC Accession No. 0001213900-24-113159
Filing Date
2024-12-27
Accepted
2024-12-27 17:10:07
Documents
15
Period of Report
2024-12-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226165-8k_citius.htm   iXBRL 8-K 34521
2 PRESS RELEASE, DATED DECEMBER 27, 2024 ea022616501ex99-1_citius.htm EX-99.1 72800
3 GRAPHIC ex99-1_001.jpg GRAPHIC 9722
  Complete submission text file 0001213900-24-113159.txt   306964

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctor-20241227.xsd EX-101.SCH 3018
5 XBRL LABEL FILE ctor-20241227_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctor-20241227_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0226165-8k_citius_htm.xml XML 3770
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-41534 | Film No.: 241586280
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)